奥翔药业(603229) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached ¥262,549,690.48, representing a 28% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥93,672,808.45, reflecting a growth of 32.45% year-over-year[5] - The net profit excluding non-recurring gains and losses was ¥92,179,290.26, which is a 30.18% increase from the previous year[5] - The basic earnings per share (EPS) was ¥0.22, up by 22.22% compared to the same period last year[5] - Total operating revenue for Q1 2023 reached ¥262,549,690.48, a 28% increase from ¥205,113,465.95 in Q1 2022[17] - Net profit attributable to shareholders for Q1 2023 was ¥93,672,808.45, representing a 32.4% increase compared to ¥70,722,644.75 in Q1 2022[18] - Basic and diluted earnings per share for Q1 2023 were both ¥0.22, up from ¥0.18 in Q1 2022[18] - The company reported a total comprehensive income of ¥93,636,753.49 for Q1 2023, compared to ¥70,711,987.61 in Q1 2022[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,902,399,186.71, a 25.36% increase from the end of the previous year[6] - Total liabilities as of Q1 2023 amounted to ¥873,763,677.27, an increase from ¥854,189,668.14 in the previous year[16] - The total assets of the company reached ¥2,902,399,186.71, up from ¥2,315,330,188.78, marking a growth of approximately 25.3%[12] - The total non-current assets amounted to RMB 1,225,118,273.88, an increase from RMB 1,178,625,030.82, which is a growth of about 3.9%[12] Shareholders' Equity - Shareholders' equity attributable to the company reached ¥2,028,635,509.44, marking a 38.84% increase year-over-year[6] - Total equity attributable to shareholders increased to ¥2,028,635,509.44 in Q1 2023, up from ¥1,461,140,520.64 in Q1 2022[16] Cash Flow - The company reported a net cash flow from operating activities of ¥44,955,913.77, attributed to an increase in received payments[7] - Cash generated from operating activities in Q1 2023 was ¥208,507,860.64, compared to ¥117,924,757.45 in Q1 2022, indicating a significant increase in cash flow[19] - The net cash flow from operating activities for Q1 2023 was ¥44,955,913.77, a significant improvement compared to a net outflow of ¥2,327,836.82 in the same period last year[20] - Total cash inflow from financing activities reached ¥573,933,781.92, compared to ¥59,150,000.00 in Q1 2022, indicating a strong increase in financing[21] - The net cash flow from investing activities was -¥81,121,541.50, slightly better than the previous year's net outflow of -¥81,471,073.66[20] - The total cash and cash equivalents at the end of Q1 2023 amounted to ¥1,065,631,248.08, up from ¥459,963,445.48 at the end of Q1 2022[21] - The company received cash from other operating activities totaling ¥69,019,109.52, compared to ¥34,357,335.06 in the previous year, reflecting a 100.5% increase[20] - Cash outflow for financing activities was ¥30,642,549.37, compared to ¥1,780,630.27 in Q1 2022, indicating a substantial rise in financing costs[21] Current Assets and Inventory - As of March 31, 2023, the total current assets amounted to RMB 1,677,280,912.83, an increase from RMB 1,136,705,157.96 as of December 31, 2022, representing a growth of approximately 47.6%[12] - The cash and cash equivalents reached RMB 1,096,813,021.14, up from RMB 608,853,480.77, indicating a significant increase of about 80.1%[11] - The accounts receivable increased to RMB 169,831,454.14 from RMB 134,812,057.22, reflecting a rise of approximately 25.9%[11] - The inventory value as of March 31, 2023, was RMB 336,187,177.39, compared to RMB 320,565,103.46 at the end of 2022, showing an increase of about 4.9%[12] Research and Development - Research and development expenses for Q1 2023 were ¥21,462,162.83, significantly higher than ¥10,600,202.65 in Q1 2022, reflecting increased investment in innovation[17] Government Subsidies - The company received government subsidies amounting to ¥810,566.08, which were closely related to its normal business operations[6] Operational Growth - The company experienced significant growth in its liver disease, antibacterial, and gout product lines, contributing to the overall profit increase[7] Guidance and Outlook - The company has not provided any specific guidance or outlook for future performance in the report[11]